October 11, 2017 Bio/Pharma/CRO Lab Top-10

MilliporeSigma Opens New Life Science Center in Massachusetts for Scientific Collaboration

Massachusetts Gov. Charlie Baker and company executive board members cut the ribbon on new Life Science Center – Burlington Company convenes scientific symposium with leaders in Genome Editing, eCommerce and Big Data New Life Science Center includes an M Lab™ Collaboration Center and region’s first BioReliance® Biodevelopment Center Burlington, Massachusetts, October 11, 2017 — MilliporeSigma today... Read more

October 10, 2017 Bio/Pharma/CRO Lab Top-10 M&A, Partnerships

Shimadzu Scientific Instruments, Inc. and VpH, a division of Vyripharm Biopharmaceuticals, Establish the Medical Botanical Center of Excellence at University of Houston Innovation Center

The First Comprehensive Botanical Testing Platform Will Ensure Quality Control/Quality Assurance, and Validation/Verification for Patient Safety and Drug Efficacy in Texas HOUSTON, Oct. 10, 2017 /PRNewswire/ — Shimadzu Instrumentation Corporation announces a collaboration with VpH, to establish the Medical Botanical Center of Excellence. The Center represents the first fully comprehensive pharmaceutical grade Medical Botanical Testing Platform in Texas. The... Read more

October 2, 2017 Bio/Pharma/CRO Microscopy Product Launch

HORIZON Particle Analysis Launches in Europe at MIBio 2017

  The HORIZON subvisible particle analysis system The HORIZON subvisible particle analysis system PHILADELPHIA, Oct. 2, 2017 /PRNewswire/ — Halo Labs announces the European launch of their new low volume, high throughput biopharmaceutical particle analysis system called the HORIZON at MIBio 2017 in Cambridge, U.K on October 4th. The new system analyzes subvisible and visible particulate matter in biopharmaceutical samples... Read more

September 27, 2017 Bio/Pharma/CRO Chromatography Lab Top-10 Product Launch

Shimadzu’s New Nexera FV Ultra High Performance Liquid Chromatograph Dramatically Reduces the Time Spent Conducting Dissolution Tests for the Development and Quality Control of Pharmaceuticals

Evaluation of the dissolution of drug products is important in the development and quality control of pharmaceuticals. Especially for generic pharmaceuticals, a dissolution test must be performed to validate their bioequivalence and whether it has been changed by the content and dosage form. Ultraviolet spectrophotometers are mainly used to measure the dissolution amount. However, a... Read more

September 27, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan

First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan Kusatsu/Shiga, Japan — September 27, 2017 — Takara Bio Inc. (Takara Bio), today announced that the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on September　26, 2017. This... Read more

September 22, 2017 Acad, Gov/Utilities Bio/Pharma/CRO Chromatography Clinical Research/Diagn. Lab Top-10 PR/Corporate

Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx SANTA CLARA, Calif., September 22, 2017 Agilent Technologies Inc. (NYSE: A) today announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by U.S. Food and Drug... Read more

September 22, 2017 Bio/Pharma/CRO Licensing, IP, and Legal

Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer

Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer (NSCLC) TECENTRIQ is a new treatment option for people with metastatic... Read more

September 22, 2017 Bio/Pharma/CRO Licensing, IP, and Legal

Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma

Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination... Read more